Literature DB >> 26935349

Pharmacokinetics of tildipirosin in pig tonsils.

F Torres1, R Santamaria2, M Jimenez2, R Menjón2, A Ibanez3, M Collell4, O Azlor4, L Fraile1,5.   

Abstract

The penetration of antimicrobials in pig tonsils is hardly known. The objective of the study was to quantify the tildipirosin (TD) penetration in tonsils. Animals were randomly divided into six groups (control, T1, T2 (1), T2(5), T2(10), and T2(15)) of eight animals. T1 and T2 groups received a dose of 2 and 4 mg of TD/kg bw in one shot (Zuprevo® MSD Animal Health), respectively, and the control group received 2 mL of saline solution. The animals were sacrificed by intravenous administration of pentobarbital sodium 24 h after finishing the treatment for the control, T1, and T2(1) groups, whereas animals of T2(5), T2(10), and T2(15) groups were sacrificed at 5, 10, and 15 days, post-treatment, respectively. Tonsils and blood samples were taken at necropsy to obtain plasma, and the tildipirosin concentration was determined by high-performance liquid chromatography with tandem mass spectrometry detection. The concentration in plasma was always significantly lower than in tonsil. Average TD tonsil concentrations increased significantly in a dose-dependent manner, and the tonsil TD vs. plasma TD concentration ratio was approximately 75 for the doses of 2 and 4 mg of TD/kg bw at 24 h post-treatment. Moreover, the maximum concentration of tildipirosin in tonsil was observed at 1 day postadministration, and this concentration decreased gradually from this day until 15 days postadministration for the dose of 4 mg of TD/kg bw. Finally, the ratio AUCtonsil/AUCplasma was 97.9, and the T1/2 (h) was clearly higher in tonsil than in plasma.
© 2015 John Wiley & Sons Ltd.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26935349     DOI: 10.1111/jvp.12258

Source DB:  PubMed          Journal:  J Vet Pharmacol Ther        ISSN: 0140-7783            Impact factor:   1.786


  3 in total

1.  Optimal Regimens and Cutoff Evaluation of Tildipirosin Against Pasteurella multocida.

Authors:  Zhixin Lei; Qianying Liu; Yi Qi; Bing Yang; Haseeb Khaliq; Jincheng Xiong; Gopi Krishna Moku; Saeed Ahmed; Kun Li; Hui Zhang; Wenqiu Zhang; Jiyue Cao; Qigai He
Journal:  Front Pharmacol       Date:  2018-07-26       Impact factor: 5.810

2.  The pharmacokinetic-pharmacodynamic modeling and cut-off values of tildipirosin against Haemophilus parasuis.

Authors:  Zhixin Lei; Qianying Liu; Bing Yang; Saeed Ahmed; Jiyue Cao; Qigai He
Journal:  Oncotarget       Date:  2017-12-07

3.  Pharmacokinetics and Pharmacodynamics of Tildipirosin Against Pasteurella multocida in a Murine Lung Infection Model.

Authors:  Dongping Zeng; Meizhen Sun; Zhoumeng Lin; Miao Li; Ronette Gehring; Zhenling Zeng
Journal:  Front Microbiol       Date:  2018-05-18       Impact factor: 5.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.